Haralambieva Iana H, Monroe Jonathon M, Ovsyannikova Inna G, Warner Nathaniel D, Grill Diane E, Poland Gregory A, Kennedy Richard B
Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, United States.
Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States.
Vaccine. 2024 Feb 6;42(4):912-917. doi: 10.1016/j.vaccine.2024.01.032. Epub 2024 Jan 17.
The responsiveness/cross-binding of vaccine-induced memory B cells/MBCs to previous and emerging divergent SARS-CoV-2 variants (e.g., Omicron) is understudied. In this longitudinal study subjects receiving two or three doses of monovalent ancestral strain-containing COVID-19 mRNA vaccine were evaluated. In contrast to others, we observed significantly lower frequencies of MBCs reactive to the receptor-binding domain/RBD, the N-terminal domain/NTD, and the S1 of Omicron/BA.1, compared to Wuhan and Delta, even after a 3rd vaccine dose/booster. Our study is a proof of concept that MBC cross-reactivity to variants with greater sequence divergence from the vaccine strain may be overestimated and suggests that these variants may exhibit immune escape with reduced recognition by circulating pre-existing MBCs upon infection.
疫苗诱导的记忆B细胞(MBCs)对既往和新出现的不同严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体(如奥密克戎)的反应性/交叉结合情况研究不足。在这项纵向研究中,我们评估了接受两剂或三剂含单价原始毒株的2019冠状病毒病(COVID-19)信使核糖核酸(mRNA)疫苗的受试者。与其他研究结果不同,我们观察到,即使在接种第三剂疫苗/加强针后,与武汉株和德尔塔株相比,对奥密克戎/BA.1的受体结合域(RBD)、N端结构域(NTD)和S1反应的MBCs频率显著更低。我们的研究证明了一个概念,即MBCs对与疫苗株序列差异更大的变体的交叉反应性可能被高估,这表明这些变体在感染时可能会通过减少循环中预先存在的MBCs的识别而表现出免疫逃逸。